MOTS-C Research Guide

MOTS-C: A Research Guide to the Mitochondrial-Derived Metabolic Peptide

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome — a member of the "mitokine" family of mitochondria-derived signaling peptides. First characterized in 2015, MOTS-C has become a prominent subject in metabolic and aging-biology research because of its reported ability to activate AMPK, a central regulator of cellular energy metabolism. This article reviews the published literature on MOTS-C strictly as a research-use-only reference.

Research Use Only. The material discussed here is intended solely for laboratory research. Nothing in this article constitutes medical advice, and no therapeutic claims are made.

What Is MOTS-C?

MOTS-C is a 16-amino-acid peptide with the sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg and a molecular weight of approximately 2,174 Da. Unlike most studied peptides, which are encoded in nuclear DNA, MOTS-C is translated from a short open reading frame within the mitochondrial 12S rRNA gene (Lee et al., 2015).

Key properties documented in the literature:

• Mitochondrial origin: Encoded in mitochondrial DNA, placing it among a small group of known mitochondria-derived peptides (sometimes called MDPs or mitokines).
• Endogenous circulation: MOTS-C is detected in human plasma, indicating it functions not only as an intracellular signal but as a systemic, endocrine-like messenger capable of reaching distant tissues.
• Age-associated decline: Multiple observational studies report that circulating MOTS-C levels decline with age in both mice and humans, with some cohorts showing reductions of 30–40% between young adults and elderly subjects.
• Exercise responsiveness: Acute exercise transiently elevates circulating MOTS-C in humans, a finding that has positioned the peptide as a candidate molecular mediator of some of exercise's metabolic effects (Reynolds et al., 2021).

How MOTS-C Works: A Distinct Route to AMPK Activation

AMPK (AMP-activated protein kinase) is a master regulator of cellular energy metabolism, often described as a metabolic switch. Many known AMPK activators work by raising the cellular AMP:ATP ratio — essentially signaling energy deficit.

MOTS-C activates AMPK through a different route. According to Lee et al. (2016), MOTS-C inhibits steps in the one-carbon folate cycle (specifically the folate-methionine cycle), causing upstream accumulation of AICAR. The monophosphate form of AICAR (ZMP) allosterically activates AMPK at its gamma-subunit — without requiring ATP depletion. This means MOTS-C can trigger the AMPK metabolic program (increased fat oxidation, improved glucose uptake via GLUT4 translocation, mitochondrial biogenesis signaling via PGC-1alpha, mTORC1 suppression) as a signaling response rather than as an energy-deficit emergency response.

This intracellular, receptor-independent mechanism distinguishes MOTS-C from most peptides encountered in the research literature and is a recurring theme in reviews of its biology.

Key Published Research on MOTS-C

The Founding Study: Metabolic Homeostasis

Lee et al. (2015), publishing in Cell Metabolism, provided the first characterization of MOTS-C. In mice fed a high-fat diet, MOTS-C administration reversed diet-induced insulin resistance and reduced obesity, effects attributed to AMPK activation. The researchers also detected MOTS-C in human plasma and reported that its levels declined with age in mice — establishing the two observations (metabolic effects, age-associated decline) that have driven the field since.

Folate-Methionine Cycle and Gene Regulation

A 2016 follow-up by Lee and colleagues in the Journal of the American Chemical Society detailed how MOTS-C regulates the folate-methionine cycle and de novo purine biosynthesis, linking mitochondrial signaling to nuclear gene expression. This work provided the mechanistic basis for the AICAR/ZMP model of AMPK activation described above.

Nuclear Translocation and Stress Responses

Kim et al. (2019), in Cell Metabolism, reported that MOTS-C translocates to the nucleus under metabolic stress and participates in adaptive gene-expression responses — extending the peptide's relevance beyond cytosolic AMPK signaling into direct transcriptional regulation.

Exercise, Aging, and Physical Capacity

Reynolds et al. (2021), in Nature Communications, reported two significant findings: that MOTS-C functions as an exercise-induced, mitochondrially encoded regulator, and that exogenous administration improved exercise performance and insulin sensitivity in aged mice. The same study documented that acute exercise elevates circulating MOTS-C in humans. Separately, D'Souza and colleagues (2022) reported that MOTS-C administration in aged mice restored exercise capacity and mitochondrial function toward levels approaching young animals.

Muscle Homeostasis

Kumagai et al. (2021), in the American Journal of Physiology — Endocrinology and Metabolism, reported that MOTS-C reduces myostatin and muscle-atrophy signaling in rodent models, extending the peptide's studied relevance to age-related skeletal muscle decline.

Early Human Data

Lee et al. (2023) published the first human trial of MOTS-C — a small, early-phase study reporting improved insulin sensitivity in overweight, sedentary men. The authors and subsequent reviewers emphasize that this was a preliminary study, and no randomized controlled trials have been completed as of 2026. MOTS-C has no FDA approval.

Observational Human Correlations

Reynolds et al. (2021) and subsequent cross-sectional plasma studies (2018–2024) have reported that circulating MOTS-C correlates inversely with age, BMI, and fasting glucose in human cohorts. Notably, some long-lived populations carry MOTS-C genetic variants associated with longevity phenotypes — an observational finding that has generated interest but establishes correlation, not causation.

MOTS-C in Longevity Research

The combination of age-associated decline, exercise responsiveness, AMPK activation, and metabolic effects has made MOTS-C a subject of active investigation in longevity biology. Researchers frame the central hypothesis as follows: if declining mitochondrial signaling competence contributes to age-related metabolic dysfunction, then a mitochondria-derived peptide that restores aspects of that signaling is worth systematic study.

It is important to state clearly what the literature does and does not support. The animal data — spanning multiple independent laboratories — consistently reports metabolic effects in rodent models. The human data is observational (correlations with age, fitness, and metabolic markers) plus one small early-phase trial. There are no completed peer-reviewed clinical trials demonstrating effects on human aging or performance outcomes.

MOTS-C Research Materials at NUPEPS PEPTIDES

NUPEPS PEPTIDES supplies MOTS-C as a lyophilized research reference material in three quantities:

• MOTS-C 10MG (lien) — suitable for pilot-scale metabolic research assays
• MOTS-C 20MG (lien) — suitable for extended in vitro research programs
• MOTS-C 40MG (lien) — suitable for larger-scale research programs

Each batch is supplied with a Certificate of Analysis documenting purity (≥99%) and identity verification. All materials are for research use only.

Evaluating MOTS-C Quality in a Research Setting

Because published findings on MOTS-C depend on the material actually studied, researchers routinely verify several quality attributes before beginning experimental work:

• Identity confirmation: Mass spectrometry should confirm the expected molecular weight (~2,174 Da) and the 16-amino-acid sequence reported in the founding literature.
• Purity assessment: Reversed-phase HPLC is the standard method for quantifying peptide purity; NUPEPS reports ≥99% purity on its Certificates of Analysis.
• Batch documentation: A batch-specific Certificate of Analysis — rather than a generic or representative document — provides the traceability needed for reproducible research.
• Lyophilized format: Freeze-dried presentation supports stability during storage and controlled reconstitution for analytical handling.

These practices reflect general standards in peptide research procurement and are not specific to any single supplier.

Questions fréquentes

What is the amino acid sequence of MOTS-C?

MOTS-C is a 16-amino-acid peptide: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg, with a molecular weight of approximately 2,174 Da. It is encoded within the mitochondrial 12S rRNA gene.

How does MOTS-C activate AMPK?

According to published work (Lee et al., 2016), MOTS-C inhibits steps in the folate-methionine cycle, causing accumulation of AICAR, whose monophosphate form (ZMP) allosterically activates AMPK — without requiring cellular ATP depletion. This distinguishes it from AMPK activators that work by raising the AMP:ATP ratio.

What is a "mitokine"?

"Mitokine" is a term used in the literature for mitochondria-derived signaling peptides — including MOTS-C and related peptides — that communicate mitochondrial status to the rest of the cell or organism. MOTS-C is notable for circulating systemically in plasma, giving it endocrine-like properties.

Why is MOTS-C studied in aging research?

Published observational data shows circulating MOTS-C declines with age, while animal studies report that administration restores metabolic parameters in aged models (Lee et al., 2015; Reynolds et al., 2021; D'Souza et al., 2022). The human evidence remains observational plus one small early-phase trial — no completed randomized controlled trials exist as of 2026.

What analytical documentation accompanies NUPEPS MOTS-C?

Each batch includes a Certificate of Analysis reporting HPLC purity (≥99%) and mass spectrometry identity confirmation.

Is MOTS-C intended for human or veterinary use?

No. NUPEPS MOTS-C is supplied strictly as a research reference material for laboratory use only. It is not intended for human or veterinary use, has no FDA approval, and no therapeutic claims are made.

References

1. Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metab. 2015;21(3):443-454.
2. Lee C, et al. "MOTS-c regulates the folate-methionine cycle and de novo purine biosynthesis." J Am Chem Soc. 2016. (Mechanistic follow-up on folate-cycle-mediated AMPK activation.)
3. Kim SJ, et al. "MOTS-c nuclear translocation and adaptive stress response." Cell Metab. 2019.
4. Reynolds JC, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nat Commun. 2021;12:470.
5. Kumagai H, et al. "MOTS-c reduces myostatin and muscle atrophy signaling." Am J Physiol Endocrinol Metab. 2021.
6. D'Souza et al. "MOTS-c restores exercise capacity in aged mice." 2022. (Aged-mouse endurance and mitochondrial function.)
7. Lee C, et al. "First human trial of MOTS-c." 2023. (Small early-phase study; insulin sensitivity in overweight sedentary men.)